KNSA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kiniksa Pharmaceuticals International PLC (KNSA) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown strong revenue growth, its declining net income and EPS, insider selling, and lack of recent positive news or catalysts make it prudent to hold off on investing right now.
The technical indicators are mixed. The MACD is above 0 and positively contracting, suggesting mild bullish momentum. The RSI is neutral at 60.992, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is near resistance levels (R1: 45.221), which could limit immediate upside potential.
The company's revenue increased significantly by 61.17% YoY in Q3 2025, and gross margin improved to 88.8%, up 8.19% YoY. These indicate strong operational performance.
Insiders are selling heavily, with a 222.25% increase in selling activity over the last month. Additionally, net income dropped significantly (-245.24% YoY), and EPS declined (-227.78% YoY). There is no recent news or event-driven catalysts to support a bullish sentiment.
In Q3 2025, revenue increased to $180.86M (up 61.17% YoY), but net income dropped to $18.44M (-245.24% YoY), and EPS fell to $0.23 (-227.78% YoY). Gross margin improved to 88.8% (up 8.19% YoY).
No recent analyst ratings or price target changes are available for KNSA.
